Abstract 412P
Background
To study of cytogenetic changes in peripheral blood lymphocytes of patients with osteosarcoma.
Methods
Studies were conducted in peripheral blood samples of 196 patients with osteosarcoma (OS) aged from 10 to 45 years. The primary cytogenetic study of patients was carried out before their clinical examination.
Results
The analysis showed that after chemotherapy, 59.5% of patients had a full and partial effect. At 46.2%, the background level of chromosomal abnormalities was less than 5% (discriminatory or dividing level), but 2.5 times higher than the average level of chromosomal abnormalities in healthy individuals. The lack of effect was observed in 40.5% of patients, and their background chromosomal abnormalities were higher than discriminatory (5%) and 7.5 times higher than in healthy individuals. A comparative analysis of the effectiveness of the treatment and the average background level of Cr-disorders among patients in this group showed that 46.2% of patients with a positive effect from chemotherapy had an average level of Cr-disorders in peripheral blood lymphocytes 2.4 times lower, than in patients with a lack of effect from this therapy.
Conclusions
The analysis showed that in the absence of the effect of the treatment carried out, the background indicators of chromosomal aberrations are significantly higher than in healthy individuals or in individuals with good clinical effect. Consequently, according to the level of chromosome aberrations in the peripheral blood lymphocytes of patients with OS identified before the start of treatment, the therapeutic effect can be predicted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ronc.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract